Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Antitumor
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Antiangiogenic
100%
Peptide Mimics
100%
Combination Treatment
100%
Tumor Angiogenic
100%
VEGF Peptide
100%
Pertuzumab
28%
Protein Level
14%
Monoclonal Antibody
14%
Tumor Development
14%
EGF Receptor
14%
Overexpression
14%
Breast Cancer
14%
Cell Viability
14%
Bevacizumab
14%
MRNA Level
14%
Tumor Growth
14%
Receptor-ligand Interaction
14%
Cancer Treatment
14%
Advanced Breast Cancer
14%
Angiogenesis
14%
Anti-tumor Response
14%
Duration of Action
14%
Mouse Tumor Model
14%
Passive Immunity
14%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
14%
Balb C Mice
14%
Peptide-based
14%
Dipeptide
14%
Retro-inverso
14%
D-amino Acids
14%
Synthesized Peptides
14%
High Efficacy
14%
Individual Treatment
14%
Long Half-life
14%
Matrigel Plug Assay
14%
Transplantable
14%
Good Target
14%
Phosphorylation Assay
14%
Designer Peptides
14%
Degradability
14%
Penetrating Ability
14%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Vasculotropin
100%
Antiangiogenic
100%
Breast Cancer
40%
Pertuzumab
40%
Amino Acid
20%
Side Effect
20%
Malignant Neoplasm
20%
Receptor
20%
Epidermal Growth Factor Receptor
20%
Monoclonal Antibody
20%
Immunotherapy
20%
Tumor Model
20%
Cell Viability
20%
Bevacizumab
20%
Tumor Growth
20%
Bagg Albino Mouse
20%
Matrigel
20%
Biochemistry, Genetics and Molecular Biology
Vascular Endothelial Growth Factor
100%
Pertuzumab
40%
Growth, Development and Aging
20%
RNA
20%
Tumor Progression
20%
Amino Acids
20%
Angiogenesis
20%
Cell Viability
20%
Epidermal Growth Factor Receptor
20%
Monoclonal Antibody
20%
Bevacizumab
20%
Receptor Blocking
20%
Bagg Albino Mouse
20%